Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using ...

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses ...

Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...

Eli Lilly now offers higher doses of its weight-loss drug Zepbound in vial form at a discount to the injector pen versions.

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly (LLY) stock in focus as the company expands Zepbound offerings with new vial formats at discounted prices. Read ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

Eli Lilly has reduced the price of its weight-loss drug Zepbound, offering higher doses in vials at a discount to boost demand and compete with Novo Nordisk's Wegovy. The price adjustment aims to ease ...

New 7.5 mg and 10 mg Zepbound single-dose vials now available for $499 per month via Zepbound Self Pay Journey Program 2.5 mg and 5 mg vial prices reduced INDIANAPOLIS ...

Joe Nadglowski, president and CEO of the Obesity Action (WA: ACT) Coalition (OAC), appreciated Lilly's efforts to make ...